News Image

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®

Provided By GlobeNewswire

Last update: Jun 4, 2025

Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane Biopharma AB (“Xbrane”), with the acqusition of the R&D organization of Xbrane in Sweden and biosimilar candidate to Cimzia® (certolizumab pegol). All regulatory conditions have been fulfilled.

Read more at globenewswire.com

ALVOTECH SA

NASDAQ:ALVO (6/13/2025, 8:00:01 PM)

After market: 9.74 0 (0%)

9.74

-0.1 (-1.02%)



Find more stocks in the Stock Screener

Follow ChartMill for more